Dose escalation of ara-C may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-α and low-dose ara-C

被引：0

作者：

Hilbe, W ^{[1
]}

Kühr, T ^{[1
]}

Apfelbeck, U ^{[1
]}

Fridrik, M ^{[1
]}

Seewann, H ^{[1
]}

Stöger, M ^{[1
]}

Linkesch, W ^{[1
]}

Pont, J ^{[1
]}

Baldinger, C ^{[1
]}

Hartner, E ^{[1
]}

Bernhart, M ^{[1
]}

Geissler, D ^{[1
]}

Krieger, O ^{[1
]}

Lang, A ^{[1
]}

Lin, W ^{[1
]}

Ludwig, H ^{[1
]}

Duba, C ^{[1
]}

Greil, R ^{[1
]}

Gastl, G ^{[1
]}

Thaler, J ^{[1
]}

机构：

[1] Univ Innsbruck Hosp, Dept Internal Med, A-6020 Innsbruck, Austria

来源：

LEUKEMIA & LYMPHOMA | 2001年 / 42卷 / 06期

关键词：

chronic myeloid leukemia; low-dose ara-C; interferon-alpha; dose escalation;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The present analysis was performed to evaluate the impact of cytosine arabinoside (ara-C) dose escalation on hematological and cytogenetic responses in patients with chronic myelogenous leukemia (CML) who failed to respond to low-dose ara-C (LD ara-C) at a dose of 10 mg/m(2)/d over 10 days per month and interferon-alpha (IFNalpha, 3.5 MU/d). Following the same administration schedule, dose escalation of ara-C to 15 and 20 mg/m(2)/d 1-10 was performed in 36 of 119 patients (30%) due to inadequate hematological response and/or disease progression. As a result, improvement of hematological and cytogenetic responses was achieved in 22 (61%) and nine (25%) patients, respectively. Escalated ara-C dose levels were usually well tolerated, although some patients experienced deterioration of preexisting side effects. Our results support the critical role of ara-C dose towards a better disease control in CML.

引用

页码：1283 / 1288

页数：6

共 18 条

[1]

ARTHUR CK, 1993, ACTA HAEMATOL-BASEL, V89, P15

[2] Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma -: phase I/II studies and pharmacokinetics [J].

Braess, J ;

Freund, M ;

Hanauske, A ;

Heil, G ;

Kaufmann, C ;

Kern, W ;

Schüssler, M ;

Hiddemann, W ;

Schleyer, E .

LEUKEMIA, 1998, 12 (10) :1618-1626

[3] Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia [J].

Guilhot, F ;

Chastang, C ;

Michallet, M ;

Guerci, A ;

Harousseau, JL ;

Maloisel, F ;

Bouabdallah, R ;

Guyotat, D ;

Cheron, N ;

Nicolini, F ;

Abgrall, JF ;

Tanzer, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04) :223-229

[4]

Guilhot F, 1998, BLOOD, V92, p627A

[5] CYTOGENETIC REMISSIONS IN CHRONIC MYELOGENOUS LEUKEMIA USING INTERFERON ALPHA-2A AND HYDROXYUREA WITH OR WITHOUT LOW-DOSE CYTOSINE-ARABINOSIDE [J].

GUILHOT, F ;

DREYFUS, B ;

BRIZARD, A ;

HURET, JL ;

TANZER, J .

LEUKEMIA & LYMPHOMA, 1991, 4 (01) :49-55

[6]

GUILHOT F, 1996, P ASCO, V15, P449

[7] TREATMENT OF ADVANCED STAGES OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA WITH INTERFERON-ALPHA AND LOW-DOSE CYTARABINE [J].

KANTARJIAN, HM ;

KEATING, MJ ;

ESTEY, EH ;

OBRIEN, S ;

PIERCE, S ;

BERAN, M ;

KOLLER, C ;

FELDMAN, E ;

TALPAZ, M .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (05) :772-778

[8] Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine [J].

Kantarjian, HM ;

O'Brien, S ;

Smith, TL ;

Rios, MB ;

Cortes, J ;

Beran, M ;

Koller, C ;

Giles, FJ ;

Andreeff, M ;

Kornblau, S ;

Giralt, S ;

Keating, MJ ;

Talpaz, M .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :284-292

[9] Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01):: a pilot study [J].

Kühr, T ;

Eisterer, W ;

Apfelbeck, U ;

Linkesch, W ;

Bechter, O ;

Zabernigg, A ;

Geissler, K ;

Barbieri, G ;

Duba, C ;

Gastl, G ;

Thaler, J .

LEUKEMIA RESEARCH, 2000, 24 (07) :583-587

[10]

Lindauer M, 1999, BRIT J HAEMATOL, V106, P1013

← 1 2 →